

---

## Lytix Biopharma - Funded Well into 2026

Redeye comments on Lytix Biopharma's Q4 report. During the quarter, Verrica reported further progress in basal cell carcinoma, the first patient was treated in NeoLIPA and Lytix raised circa NOK110m.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Lytix Biopharma - Funded Well into 2026](#)